Coming November 4: ASH publishes its abstracts and its oral and poster sessions. We’ll add the institutions presenting them as they become publicly available.

City of Hope at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

City of Hope brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 3423. Its program centres on immune therapies for blood cancers, weighing bispecific antibodies and CAR T across lymphoma and ALL. It also covers four-drug regimens for newly diagnosed myeloma and the role of tissue-resident memory T cells in graft-versus-host disease.

OrganizationASH 2026 Attendance
City of Hope
Duarte, CA
Hospitals & cancer centres
Cancer and diabetes research and treatment center founded in 1913 in Duarte, California, offering transplant, CAR T-cell therapy and clinical trials.
Booth
Exhibiting at Booth 3423
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation
Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T.
Symposium hosted by PeerView Institute for Medical Education
Leukemias · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation
CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products.
Symposium hosted by Decera Clinical Education
Lymphoma · Cell & gene
Symposium
Fri Dec 11
7:00pm–10:00pm
Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL
Continuous kinase inhibitors versus fixed-duration Bcl-2 combinations for chronic lymphocytic leukemia, weighed against recent phase 3 trial results.
Lymphoma
Symposium
Fri Dec 11
3:00pm–6:00pm
Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence
Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment.
Symposium hosted by Answers in CME
Myeloma
Talk
Coming to Trms with GVHD
Tissue-resident memory T cells that sustain chronic graft-versus-host disease, the stem-like and progenitor subsets in target organs, and how they mature.
Blood biology · Cell & gene

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from City of Hope

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction